Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China

Peize Zhang,1,2 Wei Li,3 Miaona Liu,3 Senlin Zhan,2 Hailin Zhang,2 Guofang Deng,2 Xiaoyou Chen1 1Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China; 2Department of Pulmonary Medicine and Tuberculosis, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong, P...

Full description

Bibliographic Details
Main Authors: Zhang P, Li W, Liu M, Zhan S, Zhang H, Deng G, Chen X
Format: Article
Language:English
Published: Dove Medical Press 2022-05-01
Series:Infection and Drug Resistance
Subjects:
Online Access:https://www.dovepress.com/linezolid-associated-neuropathy-in-patients-with-mdrxdr-tuberculosis-i-peer-reviewed-fulltext-article-IDR
_version_ 1818238445462487040
author Zhang P
Li W
Liu M
Zhan S
Zhang H
Deng G
Chen X
author_facet Zhang P
Li W
Liu M
Zhan S
Zhang H
Deng G
Chen X
author_sort Zhang P
collection DOAJ
description Peize Zhang,1,2 Wei Li,3 Miaona Liu,3 Senlin Zhan,2 Hailin Zhang,2 Guofang Deng,2 Xiaoyou Chen1 1Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China; 2Department of Pulmonary Medicine and Tuberculosis, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong, People’s Republic of China; 3Department of Pharmacy, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong, People’s Republic of ChinaCorrespondence: Guofang Deng; Xiaoyou Chen, Email jxxk1035@yeah.net; chenxy1998@hotmail.comObjective: Linezolid is one of the key drugs for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB). We aimed to describe the incorporation of the Michigan Neuropathy Screening Instrument (MNSI) and serum trough concentration as screening tools for neurotoxicity in the management of MDR/XDR-TB patients receiving a linezolid-based treatment regimen in Shenzhen, China.Methods: A total of 73 patients on a linezolid-containing anti–MDR/XDR-TB regimen were prospectively enrolled. The MNSI was used for peripheral neuropathy screening. Optic neuropathy was diagnosed by ophthalmologists. Serum trough concentration was recorded and its relationship with neuropathy analyzed.Results: Of all patients, neuropathy was observed in 40% (29) during anti-TB treatment. Of these, 20 (69%) had peripheral neuritis, seven (24%) optic neuritis, and two (7%) both. Serum trough concentration > 2 mg/L was observed in 17 (59%) patients with neuropathy and 13 (30%) patients without neuropathy. There was a significant statistical difference between the two groups (P=0.013). Time to onset of neuropathy from initiation of the linezolid-containing regimen was within 2 months for eight (28%) patients, 2– 6 months for 18 (62%) patients, and > 6 months for three (10%) patients. Sixteen (55%) patients were adjusted to a lower dose of 300 mg linezolid daily. Four (14%) patients had linezolid permanently removed from their regimen.Conclusion: Neuropathy is a commonly reported adverse event associated with long-term use of linezolid. MNSI and serum trough–concentration monitoring can be adopted as simple screening tools for early detection of neuropathy to balance linezolid efficacy and tolerability.Keywords: linezolid, MDR/XDR-TB, neuropathy, MNSI, serum trough concentration
first_indexed 2024-12-12T12:41:46Z
format Article
id doaj.art-90a5d20953294a35840c5c4b7eec3b0b
institution Directory Open Access Journal
issn 1178-6973
language English
last_indexed 2024-12-12T12:41:46Z
publishDate 2022-05-01
publisher Dove Medical Press
record_format Article
series Infection and Drug Resistance
spelling doaj.art-90a5d20953294a35840c5c4b7eec3b0b2022-12-22T00:24:12ZengDove Medical PressInfection and Drug Resistance1178-69732022-05-01Volume 152617262475466Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, ChinaZhang PLi WLiu MZhan SZhang HDeng GChen XPeize Zhang,1,2 Wei Li,3 Miaona Liu,3 Senlin Zhan,2 Hailin Zhang,2 Guofang Deng,2 Xiaoyou Chen1 1Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China; 2Department of Pulmonary Medicine and Tuberculosis, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong, People’s Republic of China; 3Department of Pharmacy, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong, People’s Republic of ChinaCorrespondence: Guofang Deng; Xiaoyou Chen, Email jxxk1035@yeah.net; chenxy1998@hotmail.comObjective: Linezolid is one of the key drugs for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB). We aimed to describe the incorporation of the Michigan Neuropathy Screening Instrument (MNSI) and serum trough concentration as screening tools for neurotoxicity in the management of MDR/XDR-TB patients receiving a linezolid-based treatment regimen in Shenzhen, China.Methods: A total of 73 patients on a linezolid-containing anti–MDR/XDR-TB regimen were prospectively enrolled. The MNSI was used for peripheral neuropathy screening. Optic neuropathy was diagnosed by ophthalmologists. Serum trough concentration was recorded and its relationship with neuropathy analyzed.Results: Of all patients, neuropathy was observed in 40% (29) during anti-TB treatment. Of these, 20 (69%) had peripheral neuritis, seven (24%) optic neuritis, and two (7%) both. Serum trough concentration > 2 mg/L was observed in 17 (59%) patients with neuropathy and 13 (30%) patients without neuropathy. There was a significant statistical difference between the two groups (P=0.013). Time to onset of neuropathy from initiation of the linezolid-containing regimen was within 2 months for eight (28%) patients, 2– 6 months for 18 (62%) patients, and > 6 months for three (10%) patients. Sixteen (55%) patients were adjusted to a lower dose of 300 mg linezolid daily. Four (14%) patients had linezolid permanently removed from their regimen.Conclusion: Neuropathy is a commonly reported adverse event associated with long-term use of linezolid. MNSI and serum trough–concentration monitoring can be adopted as simple screening tools for early detection of neuropathy to balance linezolid efficacy and tolerability.Keywords: linezolid, MDR/XDR-TB, neuropathy, MNSI, serum trough concentrationhttps://www.dovepress.com/linezolid-associated-neuropathy-in-patients-with-mdrxdr-tuberculosis-i-peer-reviewed-fulltext-article-IDRlinezolidmdr/xdr-tbneuropathymnsiserum trough concentration;
spellingShingle Zhang P
Li W
Liu M
Zhan S
Zhang H
Deng G
Chen X
Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
Infection and Drug Resistance
linezolid
mdr/xdr-tb
neuropathy
mnsi
serum trough concentration;
title Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
title_full Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
title_fullStr Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
title_full_unstemmed Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
title_short Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
title_sort linezolid associated neuropathy in patients with mdr xdr tuberculosis in shenzhen china
topic linezolid
mdr/xdr-tb
neuropathy
mnsi
serum trough concentration;
url https://www.dovepress.com/linezolid-associated-neuropathy-in-patients-with-mdrxdr-tuberculosis-i-peer-reviewed-fulltext-article-IDR
work_keys_str_mv AT zhangp linezolidassociatedneuropathyinpatientswithmdrxdrtuberculosisinshenzhenchina
AT liw linezolidassociatedneuropathyinpatientswithmdrxdrtuberculosisinshenzhenchina
AT lium linezolidassociatedneuropathyinpatientswithmdrxdrtuberculosisinshenzhenchina
AT zhans linezolidassociatedneuropathyinpatientswithmdrxdrtuberculosisinshenzhenchina
AT zhangh linezolidassociatedneuropathyinpatientswithmdrxdrtuberculosisinshenzhenchina
AT dengg linezolidassociatedneuropathyinpatientswithmdrxdrtuberculosisinshenzhenchina
AT chenx linezolidassociatedneuropathyinpatientswithmdrxdrtuberculosisinshenzhenchina